Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

Completed

Conditions studied: Systemic Lupus Erythematosus

In brief

The purpose of this prospective, observational cohort study is to evaluate the incidence of adverse events of special interest (AESI) and effectiveness in participants with active, autoantibody-positive SLE treated with and without BENLYSTA (belimumab). Participants will be enrolled into 1 of 2 cohorts: (1) BENLYSTA cohort: participants receiving or initiating BENLYSTA plus standard of care (SOC) at Baseline; (2) comparison cohort: participants not receiving BENLYSTA but receiving SOC at Baseline. After enrollment, changes in lupus medications, including starting or stopping BENLYSTA, are at the discretion of the physician, and all participants will continue to be followed regardless of changes in their lupus medicines until study completion. All participants will be assessed for AESI including serious infections, opportunistic infections and other infections of interest, malignancies, selected serious psychiatric events and mortality. Data will be collected at enrollment and at 6 month intervals for 5 years. BENLYSTA is a registered trademark of GlaxoSmithKline (GSK) group of companies.

Key facts

Study ID

NCT01729455

Run by

GlaxoSmithKline

People needed

3138

Starts

2013-02-21

Expected to finish

2025-02-28

Last updated by the study team

2026-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females age 18 years or older.
• Have a clinical diagnosis of active SLE.
• Current or history of autoantibody-positive SLE.
• Must be treated with SLE therapy including BENLYSTA and/or immunosuppressants (for example, azathioprine, methotrexate, cyclophosphamide, mycophenolate, and biologics).
• Have the ability to understand the requirements of the study, provide written informed consent, including consent for the use and disclosure of research-related health information, and comply with the study data collection procedures.

You may not qualify if…

• Treatment with an investigational drug within one year of enrollment. Investigational drug applies to any drug not approved for sale in the country it is being used.
• Currently enrolled in a placebo-controlled BENLYSTA (belimumab) clinical trial or a continuation protocol where belimumab is used as an investigational agent.
• Participants who have a history of BENLYSTA exposure, but are not currently receiving BENLYSTA.
• Participants only receiving an anti-malarial for SLE.
• Participants only receiving steroids for SLE.

Where it is running

• GSK Investigational Site — Glendale, Arizona, United States
• GSK Investigational Site — Goodyear, Arizona, United States
• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Prescott, Arizona, United States
• GSK Investigational Site — Sun City, Arizona, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Bakersfield, California, United States
• GSK Investigational Site — La Mesa, California, United States
• GSK Investigational Site — Lakewood, California, United States
• GSK Investigational Site — Loma Linda, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Murrieta, California, United States
• GSK Investigational Site — Pomona, California, United States
• GSK Investigational Site — Upland, California, United States
• GSK Investigational Site — West Hills, California, United States
• GSK Investigational Site — Danbury, Connecticut, United States
• GSK Investigational Site — New Haven, Connecticut, United States
• GSK Investigational Site — Orangeburg, Connecticut, United States
• GSK Investigational Site — Brandon, Florida, United States
• GSK Investigational Site — Clearwater, Florida, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.